<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="20510">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02839889</url>
  </required_header>
  <id_info>
    <org_study_id>D3820C00041</org_study_id>
    <nct_id>NCT02839889</nct_id>
  </id_info>
  <brief_title>Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and OIC (Opioid Induced Constipation)</brief_title>
  <official_title>A Study to Assess the Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and Opioid-Induced Constipation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospice of Henderson County, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospice of Henderson County, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if naloxegol can be used in the treatment of
      opioid-induced constipation in patients with cancer and pain. This phase 4 study consists of
      a two week randomized double blind period followed by a two week open-label period.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Occurrences from Baseline through study completion, approximately 6 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Numerical Rating Scale (NRS) for Pain change from Baseline</measure>
    <time_frame>Assessed from screening/Opioid Induced Constipation (OIC) Confirmation period through study completion, approximately 6 weeks.</time_frame>
    <description>Change from baseline in mean daily NRS values will be calculated as the post-baseline value minus the baseline. Baseline NRS is the mean daily NRS values recorded during the Opioid Induced Constipation (OIC) Confirmation period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Daily Opioid Use change from Baseline</measure>
    <time_frame>Assessed from screening through study completion, approximately 6 weeks.</time_frame>
    <description>Change from baseline in mean daily opioid dose will be calculated as the post-baseline value minus the baseline value. Positive changes from baseline indicate need to increase the opioid dose. Baseline daily opioid dose is the mean daily opioid dose recorded during the Opioid Induced Constipation (OIC) Confirmation period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events associated with Blood Laboratory result changes from Baseline</measure>
    <time_frame>Change from Baseline at End of Double Blind Phase (Visit 3, approximately day 15)</time_frame>
    <description>Changes from Baseline to Visit 3 (approximately Day 15) for all patients will be calculated as the post-baseline test value minus the baseline test value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Electrocardiogram (ECG) Interval and Rate Change from Baseline</measure>
    <time_frame>Change from Baseline at End of Double Blind Phase (Visit 3, approximately day 15)</time_frame>
    <description>Changes from Baseline to Visit 3 (approximately Day 15) for Electrocardiogram (ECG) interval data and rate data will be derived by subtracting the baseline value from the final assessment data.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital Signs changes from Baseline</measure>
    <time_frame>Change from Baseline in vital signs (sitting blood pressure, pulse, and respiratory rate) through study completion, approximately 6 weeks.</time_frame>
    <description>Change from Baseline in vital signs (sitting blood pressure, pulse, and respiratory rate)at post baseline (visits 2, 3, 4) will be derived as the value at the visit minus the baseline value for the same assessment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rescue Free Bowel Movements (RFBM) Responder Rate</measure>
    <time_frame>Assessed from Baseline through Study Completion, approximately 6 weeks.</time_frame>
    <description>Daily diary data will be used to identify RFBMs. The weekly RFBM frequency within each time period will be calculated as: (Total number of RFBMs during the time period of interest/number of days) x 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Post-dose Rescue Free Laxation</measure>
    <time_frame>Time (in hours) to first post-dose rescue free bowel movement minus first dose date and time.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bristol Stool Scale (BSS) Score</measure>
    <time_frame>Assessed from baseline through Study Completion, approximately 6 weeks.</time_frame>
    <description>Calculated as the sum of daily values for the interval divided by the number of days within the interval in which the data were collected. Change from baseline in the mean BSS score will be calculated. Positive changes from baseline indicate improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Assessment of Constipation Symptoms (PAC-SYM)</measure>
    <time_frame>day 1, day 15, day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Assessment of Constipation Quality of Life (PAC-QOL)</measure>
    <time_frame>day 1, day 15, day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of Straining question with each Bowel Movement</measure>
    <time_frame>Assessed at baseline through Study Completion with each bowel movement, approximately 6 weeks.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Evacuation question with each Bowel Movement</measure>
    <time_frame>Assessed at baseline through Study Completion with each bowel movement, approximately 6 weeks.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Cancer</condition>
  <condition>Constipation</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo once daily for two weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naloxegol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Naloxegol 25mg tablets once daily for two weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naloxegol</intervention_name>
    <description>Naloxegol 25mg tablets for two weeks, followed by a two week open-label period</description>
    <arm_group_label>Naloxegol</arm_group_label>
    <other_name>Movantik</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo once daily for two weeks, followed by two week open-label period</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women aged 18 or older: Women of child bearing potential must have a negative
             urine pregnancy test during the Screening/Opioid Induced Constipation (OIC)
             Confirmation/Baseline period, a history of no sexual activity or consistent use of an
             effective birth control method for at least 12 weeks prior to the study, and
             agreement that no sexual activity or the method of birth control will be continued
             during the study and for a period of 8 weeks after it ends; male patients who are
             sexually active must agree to use a barrier method of contraception (condom with
             spermicide) from the first dose of Investigational Product until 12 weeks after their
             last dose

          -  Able to follow instructions in English, give informed consent and to answer patient
             reported outcomes (PRO) questions by himself/herself; the patient will provide
             written informed consent before initiation of any study-related procedures

          -  Active cancer of any type with an investigator-estimated life expectancy ≥ 8 weeks
             and a Palliative Performance Status scale score ≥ 30%

          -  Patients receiving concurrent chemotherapy must have received and recovered from a
             minimum of 1 cycle of the current chemotherapy regimen upon consenting to the study
             and be considered stable in the opinion of the investigator

          -  Chronic cancer-related pain, defined as pain for a minimum of ≥2 weeks which on
             review by the investigator, can be attributed to the neoplasm or its treatment

          -  Daily treatment with an opioid drug which is taken at a dose equal to or greater than
             20 milligrams (mg) of morphine or its equivalent for at least one week, with no
             day-to-day daily fluctuation greater than 25% and no expectation of a decrease
             greater than 25% or an increase greater than 50% during the study period.

          -  Patients may or may not be on a stable laxative regimen, defined as daily use at a
             stable dose for &gt;7 days; if the patient is taking a stable dose, he or she must be
             willing to remain on that regimen for the 7 day confirmation period without titration
             or adjustments.

          -  History of constipation, defined through history and through participation in the OIC
             Screening/OIC Confirmation/Baseline period

               -  Patient history must include fewer than 3 rescue-free bowel movements (RFBM) per
                  week during the two weeks prior to screening and experiencing at least one of
                  the following symptoms during at least one-quarter of the Bowel Movements (BM)
                  experienced during the prior two weeks: hard/lumpy stools, straining, or
                  sensation of incomplete evacuation/anorectal obstruction (rescue-free BMs are
                  defined as using a laxative if not already taking daily laxatives, or if taking
                  daily laxatives, using an additional laxative).

               -  Confirmation during the 7-day OIC confirmation period must include the
                  experience &lt;3 rescue-free BMs plus a report ≥ 1 of the following symptoms during
                  at least 1 BM recorded in the diary during the OIC confirmation period: Bristol
                  Stool Scale (BSS) stool type 1 or 2; moderate, severe, or very severe straining;
                  incomplete BM.

        Exclusion Criteria:

          -  Cancer-related/medical comorbidity-related

               -  Patients with a past or current history of intra-abdominal neoplasm AND clinical
                  findings that, on review by the investigator, may increase the risk of bowel
                  perforation

               -  An active condition associated with clinically significant brain pathology,
                  including known brain metastases, meningeal metastases, past traumatic brain
                  injury, multiple sclerosis, uncontrolled epilepsy with signs or symptoms of
                  compromised blood brain barrier

               -  Patients expected to undergo a first course of a chemotherapy regimen during the
                  study period, patients who received a vinca alkaloid within 2 months, patients
                  who have any history of vinca-associated GI autonomic neuropathy and/or
                  constipation, or patients receiving a chemotherapy regimen including a
                  VEGF-inhibitor (e.g., bevacizumab, sorafenib).

               -  Requiring radiation therapy between the diaphragm and pelvis 2 weeks prior to
                  Visit 1 (screening) and/or during the study

               -  Any other significant and/or progressive condition (medical, neurological,
                  psychiatric or metabolic) or symptom that could increase the risk of
                  participation in the study or affect the interpretation of study data as
                  determined by the investigator (e.g., uncontrolled hypothyroidism, inadequately
                  controlled clinical depression, poorly controlled seizure disorder)

               -  Hemorrhagic diathesis

               -  Expected to have a surgical procedure requiring general anesthesia during the
                  study period

          -  Other gastrointestinal disorders

               -  Medical conditions and treatments, which in the judgment of the investigator,
                  may be associated with diarrhea, intermittent loose stools, or constipation,
                  (e.g., active diverticular disease, peritonitis of any cause, inflammatory bowel
                  disease, active irritable bowel syndrome, chronic idiopathic constipation).

               -  Any conditions that could affect the absorption or metabolism of the study drug
                  (e.g., malabsorption syndrome, severe liver disease) as judged by the
                  investigator

               -  Evidence of fecal impaction either by physical or x-ray exam

               -  Known or suspected mechanical GI obstruction

               -  Current peritoneal catheter for intra-peritoneal chemotherapy or dialysis

               -  Fecal ostomy

               -  History of fecal incontinence

               -  History of bowel surgery within 60 days of the screening period

               -  Any other potential non-opioid cause of bowel dysfunction that in opinion of
                  investigator might be a contributor to the constipation

          -  Pain-related

               -  Receiving opioid medication on less than daily dosing schedule only

               -  Severe background pain (eg, typical average daily pain intensity rating of 8 to
                  10 on an 11-point NRS) refractory opioid therapy

          -  Any of the following findings or conditions between the enrollment and randomization
             visits:

               -  Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt;2.5 x
                  upper limit normal (ULN) and/or serum bilirubin &gt;2 x ULN (unless elevation is
                  due to Gilbert's syndrome)

               -  Calculated Creatinine clearance &lt;30 ml/min

               -  A Fridericia corrected QT interval (QTcF) &gt; 500 msec at screening, history of
                  myocardial infarction within 6 months before randomization, symptomatic
                  congestive heart failure despite treatment, unstable angina, or symptomatic
                  peripheral vascular disease

               -  Active substance or alcohol use that, in the opinion of the investigator, may
                  compromise patient's ability to comply with the study instructions

               -  Use of prohibited medications as listed in Section 5.5

               -  Pregnancy or lactation

               -  Known history of intolerance or hypersensitivity to alvimopan, methylnaltrexone,
                  or other peripherally acting opioid antagonists or to any other component in the
                  tablets

               -  Involvement in the planning and/or conduct of the study (applies to AstraZeneca
                  staff, staff at the study site, and third-party vendors)

               -  Any receipt of an investigational medication within 30 days of screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janet Bull, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospice of Henderson County, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Janet Bull, MD</last_name>
    <phone>8286926178</phone>
    <email>jbull@fourseasonscfl.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lisa Massie</last_name>
    <phone>8286926178</phone>
    <email>lmassie@fourseasonscfl.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>MJHS Institute for Innovation in Palliative Care</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Russell Portenoy, MD</last_name>
      <phone>212-649-5500</phone>
    </contact>
    <investigator>
      <last_name>Russell Portenoy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospice of Henderson County, Inc</name>
      <address>
        <city>Flat Rock</city>
        <state>North Carolina</state>
        <zip>28731</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janet Bull, MD</last_name>
      <phone>828-692-6178</phone>
    </contact>
    <investigator>
      <last_name>Janet Bull, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospice of the Western Reserve, Inc.</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Charles Wellman, MD</last_name>
      <phone>216-383-2222</phone>
    </contact>
    <investigator>
      <last_name>Charles Wellman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 15, 2016</lastchanged_date>
  <firstreceived_date>June 17, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospice of Henderson County, Inc.</investigator_affiliation>
    <investigator_full_name>Janet Bull</investigator_full_name>
    <investigator_title>Chief Medical Officer</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Constipation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Naloxegol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
